Saturday, June 25

Pfizer and BioNTech point out that the third dose neutralizes the Omicron variant

Pfizer and BioNTech reported today that initial laboratory studies show that atThe third dose of its Covid-19 vaccine neutralizes the Omicron variant, results that will accelerate booster campaigns around the world.

A booster with the current version of the vaccine raises antibodies 25-fold, providing a level similar to that seen after two doses against the parent virus and other variants, the companies said. The so-called T cells still provide protection against serious diseases, they said.

Nevertheless, The partners said they are confident they will have a specific version of the Omicron vaccine ready for delivery in March 2022.

The results show that A third injection can, at least in part, repair the holes in the body’s defenses against Omicron after the initial two doses. Uncertainty about the efficacy of the vaccine against the new variant has fueled market volatility and led to travel restrictions since Ómicron was identified in southern Africa last month.

“From this preliminary data, it is clear that protection improves with a third dose,” said the Pfizer CEO. Albert Bourla in a statement. Initial data shows that a third dose could still offer sufficient protection against illnesses stemming from the virus, said BioNTech CEO Ugur Sahin.

The data is preliminary, as partners continue to study the new variant. People vaccinated with two doses may still be protected against severe forms of Covid from the Omicron variant, thanks to T cells that are unaffected by the variant mutations, the companies said.

Leave a Reply

Your email address will not be published.